NRGene & Tel Aviv Medical Center Collaborate on Parkinson’s

NRGene and Tel Aviv Sourasky Medical Center Collaborate on Parkinson’s Genomes

Tel Aviv Sourasky Medical Center and NRGene research exploring protection again neurodegenerative disease

Tel Aviv & Ness Ziona, Israel – 30 November 2017 – NRGene, the worldwide leader in genomic assembly and analysis, has partnered with the Genetic Institute of Tel Aviv Sourasky Medical Center (TASMC) to perform genomic analysis of Parkinson’s disease (PD).

“Our collaboration with NRGene and use of its advanced technology allows us to do comprehensive genetic research on Parkinson’s,” said Professor Avi Orr-Urtreger, director of TASMC Genetic Institute. “The GenoMAGICTM system will allow us to characterize the genetics of the cohort completely and efficiently.”

TASMC is leading successful combined clinical and genetics research aiming for better understanding, treatment, and prevention of Parkinson’s disease. This 12-year-old collaboration between the department of Neurology (Prof. Nir Giladi) and the Genetic Institute has already yielded international collaboration and support, as well as dozens of scientific publications. Currently, the study cohort in TASMC includes thousands of individuals and a wealth of data.

NRGene’s GenoMAGICTM, a cutting-edge cloud-based genomic analytic system, will efficiently analyze the genomic data of a Parkinson’s patients cohort and identify individuals’ unique genomic makeup. Correlating genomic differences with disease phenotypes could reveal novel PD-related genes and the interaction between multiple genetic and environmental risk factors.

“NRGene has already proven its ability to analyze large scale genomic datasets and accurately identify key genes and mutations affecting individuals,” said NRGene CEO Gil Ronen. “We are proud that our unique genomic tools are supporting genetic studies of Parkinson’s disease. The identification of genes involved in the development of the disease will improve our understanding of it and will potentially lead to new drug targets and treatment strategies.”

ENDS

About NRGene

NRGene is a genomic big data company developing cutting-edge software and algorithms to reveal the complexity and diversity of humans, plants and animals for supporting the most advanced medical research and sophisticated breeding programs. NRGene tools have already been employed by some of the leading seed companies worldwide as well as the most influential research teams in academia. www.nrgene.com.

© Scoop Media